Bioactive metabolites: A clue to the link between MASLD and CKD?
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0782 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Wen-Ying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Fatty Liver. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Top Talent Support Program for young and middle-aged people of Wuxi Health Committee and scientific technological innovation and venture capital fund in Wuxi.
Abstract (Originalsprache)
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Wuxi, Jiangsu, China.
- Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK.
- Department of Medicine, University of Verona, Verona, Italy.
- Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.
- Intensive Care Medicine, Jiangnan University Medical Center, Wuxi, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Top Talent Support Program for young and middle-aged people of Wuxi Health Committee and scientific technological innovation and venture capital fund in Wuxi
- scientific technological innovation and venture capital fund in Wuxi
- School of Medicine, University of Verona
- National Institute for Health and Care Research
Zitieren
APA
Chen, W. Y., Zhang, J. H., Chen, L. L., Byrne, C. D., Targher, G., Luo, L., Ni, Y., Zheng, M. H., & Sun, D. Q. (2025). Bioactive metabolites: A clue to the link between MASLD and CKD?. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0782
Vancouver
Chen WY, Zhang JH, Chen LL, Byrne CD, Targher G, Luo L, et al. Bioactive metabolites: A clue to the link between MASLD and CKD?. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0782
BibTeX
@article{Chen2025,
author = {Chen, Wen-Ying and Zhang, Jia-Hui and Chen, Li-Li and Byrne, Christopher D and Targher, Giovanni and Luo, Liang and Ni, Yan and Zheng, Ming-Hua and Sun, Dan-Qin},
title = {Bioactive metabolites: A clue to the link between MASLD and CKD?},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0782}
}
EUVIMED